Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2013

View Archived Issues

First-in-human study results of ISIS-SMNRx in children with spinal muscular atrophy

Spanish researchers develop new combinatorial drug delivery and neuronal activity recording probe

Ohr Pharmaceutical reports results from phase II trial of OHR/AVR-118 in cancer cachexia

Potential benefit demonstrated for tamoxifen in mouse model of DMD

FDA and EMA set to review Piramal Imaging's marketing applications

Threshold set to acquire Siemen's investigational hypoxia PET imaging agent

SD-809 demonstrates improved pharmacokinetic profile in healthy volunteers

BIO5-TGen forms collaboration focused on drug development for Alzheimer's disease

Photochemical internalization of bleomycin using TPCS2a

Biotest to begin phase IIb trial of tregalizumab in rheumatoid arthritis

Parent Project Muscular Dystrophy funds research for potential new DMD treatment

RaQualia and Carna Biosciences form drug discovery collaboration

Implantation of encapsulated NGF-releasing cells safe and well tolerated in patients with AD

CHMP recommends approval of rivaroxaban in new indication

CHMP recommends against E.U. approval of Gentium's defibrotide

European CHMP recommends restriction on use of cilostazol-based medicines

Intrathecal idursulfase proves effective in children with Hunter's syndrome

Viamet Pharmaceuticals discloses new cytochrome P450 inhibitors

IRM discloses novel protein kinase inhibitors

Roche prepares new JAK3/SYK protein kinase inhibitors

Merz Pharma presents novel glycine B receptor antagonists

Arzerra approved in Japan

FDA denies approval of oral treprostinil in PAH

Regorafenib approved in Japan for colorectal cancer

NDA submitted for empagliflozin in type 2 diabetes

Xeljanz obtains approval in Japan for rheumatoid arthritis

MST-188 obtains orphan drug designation in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...